Scientific Evidence Lacking for Patients Choosing Among Treatments for Narrowed Kidney Arteries

Press Release Date: October 24, 2006

Increasing numbers of patients with narrowed kidney arteries are undergoing vessel-widening angioplasty and placement of a tubular stent, but the latest scientific evidence does not show a clear advantage of that treatment over prescription drug therapy, according to a new review funded by the Agency for Healthcare Research and Quality (AHRQ). An article based on the review is posted today in the online version of the Annals of Internal Medicine.

Narrowed kidney arteries—a condition known as renal artery stenosis (RAS)—are the most common cause of correctable high blood pressure. The progressive condition reduces the supply of blood to the kidneys. In most cases the problem is caused by atherosclerosis, the gradual build-up of fat-containing plaque. RAS may occur alone or in combination with high blood pressure and chronic kidney disease. It is found in about 30 percent of patients with coronary artery disease and up to 50 percent of seniors or people who have diffuse atherosclerotic vascular diseases.

RAS patients have three treatment options: angioplasty, which reopens the narrowed artery with a small balloon; angioplasty in combination with a stent, a metal mesh tube placed inside the artery; or therapy with drugs, such as angiotensin converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), calcium channel blockers, and/or beta blockers. Some doctors also recommend statins to lower cholesterol, or antiplatelet medicines, such as aspirin. Patients treated only with drugs, which may need to be taken for a lifetime, can experience diminished kidney function due to RAS. That can lead to sickness and death, and these patients may be at increased risk of heart disease. However, it is unclear whether angioplasty leads to better outcomes for most patients.

While many RAS patients are treated with drugs, a growing number of RAS patients are opting for angioplasty. Medicare data show that angioplasty more than doubled from 7,660 in 1996 to 18,520 in 2000. The average charge of RAS angioplasty done in the hospital was $27,800 in 2004, according to data from AHRQ's Healthcare Cost and Utilization Project. The procedure, like any surgery, carries risks of complications or even death. In addition, the durability of benefits of angioplasty with or without a stent is unclear.

Authors of the systematic literature review concluded that a shortage of direct comparisons between drug therapy and angioplasty has left important questions unanswered, including which therapy is more likely to improve kidney function. The U.S. Department of Health & Human Services' (HHS) National Institutes of Health has launched a large clinical trial to compare the benefits of angioplasty with stent placement versus drug treatment, but results are not expected until 2010.

"In an ideal world, doctors and patients confronting an illness should be able to draw upon reliable scientific evidence to make treatment decisions," said AHRQ Director Carolyn M. Clancy, M.D. "Unfortunately, renal artery stenosis is among those for which evidence is lacking. This new review serves an important purpose by identifying where research is needed."

AHRQ's new review of published studies, completed by the Agency's Tufts-New England Medical Center Evidence-based Practice Center, has concluded:

• Available evidence on RAS treatments is inadequate to clearly support angioplasty, with or without a stent, over drug therapy. No studies have directly compared the use of stents versus medications.
• The published literature did confirm that drug therapy and angioplasty both improve blood pressure, and they have similar impacts on slowing down the worsening of kidney function. But actual improvements in kidney function have only been reported in angioplasty studies that lacked direct comparisons with other therapies.
• For people with stenosis in both renal arteries, angioplasty may control blood pressure better than drug therapy alone.
• The evidence is inadequate to determine whether the treatments differ in lowering the risks of death, kidney failure, or heart disease.
• The risks of adverse events have not been adequately measured. Some studies suggested up to 3 percent of angioplasty patients died within 30 days. Other risks of angioplasty include kidney deterioration, injury to the renal artery or kidney tissue, and heart attack.
• Adverse events related to blood pressure medications (ACE inhibitors, beta blockers, and hydralazine) include dizziness when standing, problems with the digestive or nervous systems, and Raynaud's syndrome, which restricts blood flow to the fingers and toes.

The new review, titled Comparative Effectiveness of Management Strategies for Renal Artery Stenosis, is the newest in a series of Comparative Effectiveness Reviews produced by AHRQ's Effective Health Care Program. The Effective Health Care program is the first federal effort to provide patients, health care providers, policymakers and others with evidence comparing treatment options and other interventions for common health conditions. Visitors to the program's Web site, http://www.effectivehealthcare.ahrq.gov, can nominate topics for future reviews, submit comments on draft reviews, or sign up to be notified when new reviews are available. Copies of executive summaries may be obtained by calling AHRQ's Publications Clearinghouse at (800) 358-9295 or sending an E-mail to AHRQPubs@ahrq.hhs.gov. Summaries and full reports are available at the Effective Health Care Web site.

For more information, please contact AHRQ Public Affairs: (301) 427-1998 or (301) 427-1865.

---

Internet Citation:

Scientific Evidence Lacking for Patients Choosing Among Treatments for Narrowed Kidney Arteries. Press Release, October 24, 2006. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/news/press/pr2006/kidneypr.htm

---